LDS/Medical Tests/Primary Hyperoxaluria Gene Mutation Panel

Primary Hyperoxaluria Gene Mutation Panel

Primary hyperoxalurias (PH) are rare, autosomal recessive disorders of glyoxylate metabolism that result an excess production of oxalate which is poorly soluble and deposits as calcium oxalate in various tissues. Excessive excretion of oxalate by the kidneys can result in renal stones, recurrent nephrolithiasis, nephrocalcinosis, and may progress to end-stage renal disease (ESRD). There are three types of primary hyperoxalurias: PH1, PH2, and PH3 due to mutation in the genes AGXT, GRHPR, and HOGA1 respectively.

Primary hyperoxaluria type 1 (PH1) accounts for approximately 70% of cases and is inherited in an autosomal recessive manner. PH1 is caused by mutations in the AGXT gene at 2q36-37 which codes for the enzyme alanine: glyoxylate-aminotransferase (AGT) which converts glyoxalate to glycine. Over 190 mutations have been identified, most of which are missense mutations that result in complete absence of the enzyme resulting in an increased pool of glyoxlate that is subsequently converted to oxalate. PH1 is the most severe form of the disease with early onset renal damage progressing to ESRD. As the glomerular filtration rate falls systemic oxalosis occurs with calcium oxalate deposited in joints, bones, heart, blood vessels and the retina.

Primary hyperoxaluria type 2 (PH2), is associated with mutations in the GRHPR gene at position 9p13.2 that cause a deficiency of the enzyme glyoxylate reductase/hydroxypyruvate reductase (GR/HPR). Symptom onset typically occurs in childhood, but progression ESRD only occurs in 25-35% of patients.

Primary hyperoxaluria type 3 (PH3), is caused by mutations in the HOGA1 gene at 10q24.2 that codes for 4-hydroxy-2-glutarate aldolase 1 (HOGA1). The enzyme catalyzes the final step in the metabolism of hydroxyproline, releasing glyoxalate and pyruvate. The disease typically has its onset in childhood or adolescence with recurrent kidney stones, but patients typically do not progress to ESRD.

Recurrent kidney stones and/or a family history of oxalate renal stones are a strong indication for primary hyperoxaluria panel testing. The panel should include analysis of all three genes AGXT, GRHPR, and HOGA1 associated with primary hyperoxaluria.

  • Confirmation of primary hyperoxaluria
  • Differentiating the type of primary hyperoxaluria
  • Carrier testing for at-risk relatives
  • Prenatal testing for pregnancy at increased risk

Positive: Mutation in the AGXT, GRHPR, and/or HOGA1 gene indicating primary hyperoxaluria susceptibility.

Negative: No mutation in the AGXT, GRHPR, and/or HOGA1 gene indicating primary hyperoxaluria susceptibility.

Negative for mutations analysis (no mutations or pathogenic variants detected)

Target Next Generation Sequencing (NGS), Sanger Sequencing, Multiplex Real-time PCR (ARMS).

Whole blood collected in EDTA (Lavender top tube).

Stability

  • Ambient: 3-4 days
  • Refrigerated: 7-14 days
  • Frozen: unstable
Urine oxalate level, plasma oxalate level, renal stone analysis, renal biopsy, urine routine examination, urine glyoxylate, AGT/HOGA1/GRHPR activity in liver biopsy tissue.
1 - 2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • J Am Soc Nephrol. 2001 Oct;12(10):2072-2079. [PMID: 11562405]
  • World J Nephrol. 2015;4(2):235-244. [PMID: 25949937]
  • Nefrologia. 2014;34(3):398-412. [PMID: 24798559]
  • Clin Kidney J. 2022 May 17;15(Suppl 1):i17-i22. [PMID: 35592618]
  • GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022. [PMID: 20301460]
  • National Organization for Rare Disorders. (2003). NORD guide to rare disorders. Primary hyperoxaluria; Philadelphia: Lippincott Williams & Wilkins.